GLP1 agonists and SGLT2 inhibitors in heart failure management

The clinical evidence points to different strengths: SGLT2 inhibitors have a consistent record of reducing heart-failure hospitalizations across ejection-fraction groups, while semaglutide has shown meaningful gains in symptoms, physical function, and weight for people with obesity and HFpEF.

That distinction matters at the bedside. A patient may need help avoiding another admission, improving exertional symptoms, managing diabetes, or addressing obesity that is making daily activity harder. Those goals overlap, but they are not identical. When I discuss GLP-1 receptor agonists vs SGLT2 inhibitors in heart failure, I start with the heart-failure phenotype and the outcome we are trying to change, then consider metabolic health alongside it.

Why SGLT2 inhibitors anchor heart-failure treatment

Dapagliflozin and empagliflozin were first recognized as glucose-lowering medicines, but their heart-failure evidence extends beyond diabetes care. Randomized trials have shown reductions in heart-failure hospitalization and cardiovascular mortality in people with reduced ejection fraction and in those with preserved ejection fraction. The benefit has also been observed in people without type 2 diabetes.

Across the trials summarized in the evidence base, SGLT2 inhibitors were associated with a relative risk reduction of roughly 30–35% in heart-failure hospitalization and cardiovascular mortality outcomes. In EMPEROR-Preserved, empagliflozin reduced heart-failure-related hospitalizations by 29% among patients with HFpEF. These are relative reductions, not a promise that every individual will avoid an admission; a person’s absolute benefit depends in part on their underlying risk.

In my clinic, I explain the result this way: heart failure changes how the body handles fluid and responds to strain, and an SGLT2 inhibitor can improve the clinical course even when blood sugar is not the main problem. The exact biological pathways are still an area of study. For a treatment decision, the more useful point is that the outcome evidence reaches across diabetes status and ejection-fraction categories.

That breadth is why dapagliflozin or empagliflozin often enters the conversation early when we are considering disease-modifying therapy for heart failure. It does not mean these drugs replace every other part of care. Heart-failure management still depends on the person’s symptoms, other conditions, current medicines, and the clinician’s assessment of what is safe and appropriate.

For preventing heart-failure events, the SGLT2 evidence is broader; for obesity-related symptoms and function in HFpEF, semaglutide adds a different kind of value.

Semaglutide addresses a different part of HFpEF

HFpEF can be difficult to manage because a normal or near-normal ejection fraction does not mean that a person feels well or can exercise comfortably. Obesity may add to the burden through its effects on mobility, metabolic health, and the demands placed on the cardiovascular system. In this setting, weight reduction and improved physical function can matter greatly to the patient’s daily life.

The STEP-HFpEF trial studied weekly semaglutide at a dose of 2.4 mg in people with obesity and HFpEF, including participants without type 2 diabetes. Over 52 weeks, semaglutide improved heart-failure-related symptoms, physical limitations, exercise capacity, and body weight. Those outcomes speak to how a patient feels and functions, which is clinically meaningful even though they do not establish that semaglutide prevents heart-failure admissions to the same extent as an SGLT2 inhibitor.

This is where the phrase metabolic modulation in heart failure management becomes useful, provided we keep it grounded. Semaglutide can help address obesity and related metabolic factors; it should not be presented as a substitute for therapies with established heart-failure event reduction. In the available comparison, its strongest heart-failure-specific case is for people with HFpEF and obesity whose symptoms and physical limitations remain important treatment targets.

Patients sometimes ask whether the weight effect means the heart itself is “fixed.” I would frame it more carefully. Better weight and improved exercise capacity may make daily movement more manageable and may improve the overall metabolic environment. They do not, by themselves, prove that the underlying heart-failure risk has been reduced to the same degree as with a therapy tested for hospitalization outcomes.

Nor should the STEP-HFpEF findings be casually carried over to HFrEF. The evidence described here does not establish semaglutide as a primary alternative to an SGLT2 inhibitor for reducing heart-failure hospitalization in HFrEF. When discussing cardiovascular outcomes of semaglutide in HFrEF, the responsible answer is that this comparison does not provide a basis for claiming equivalent heart-failure event protection.

Compare the outcome, not just the drug class

A common source of confusion is treating “benefit” as one outcome. Trials may measure hospitalizations, cardiovascular mortality, symptoms, exercise capacity, or weight. Those outcomes are related, but a change in one does not automatically establish a change in another.

For a person with HFrEF, the evidence presented here supports SGLT2 inhibitors as an important heart-failure therapy, whether or not type 2 diabetes is present. For a person with HFpEF and obesity, semaglutide may address a substantial symptom and functional burden. If the person also has diabetes and cardiovascular disease, glucose management and broader cardiovascular and renal protection become part of the discussion, but the drugs still have distinct evidence profiles.

A practical way to read the clinical trial data on heart failure pharmacotherapy is to ask three questions:

1. Which heart-failure phenotype was studied? Results in HFrEF should not be assumed to apply unchanged to HFpEF, or vice versa.

2. What outcome improved? Fewer hospitalizations and better exercise capacity are both worthwhile, but they answer different clinical questions.

3. What patient group was enrolled? The STEP-HFpEF results apply to people with obesity and HFpEF, including those without type 2 diabetes; they do not establish a universal semaglutide effect across all heart-failure populations.

For a patient with type 2 diabetes and underlying cardiovascular disease, the comparative evidence summarized here indicates that SGLT2 inhibitors provide greater reductions in heart-failure hospitalization than GLP-1 receptor agonists. That is a useful distinction when the immediate concern is another admission. It does not erase the possible value of a GLP-1 receptor agonist for weight management or metabolic health.

Dapagliflozin versus GLP-1 therapy for heart failure is therefore not a simple contest with one winner for every patient. If the question is which class has the more consistent evidence for reducing heart-failure hospitalization across ejection-fraction groups, the advantage belongs to SGLT2 inhibitors. If the question is whether semaglutide can improve symptoms, physical limitations, exercise capacity, and weight in people with HFpEF and obesity, STEP-HFpEF provides supportive evidence.

When combination therapy enters the picture

Some patients have overlapping needs: heart failure, type 2 diabetes, obesity, and kidney or cardiovascular risk. In that setting, clinicians may consider both an SGLT2 inhibitor and a GLP-1 receptor agonist, with each medicine serving a distinct purpose. Available real-world data and clinical studies indicate that combination therapy can provide additive cardiovascular and renal protective benefits without an increase in major adverse safety events in the populations examined.

That finding is encouraging, but it should be read at the right level of certainty. It does not prove that every patient should receive both medicines, nor does it establish a single combined regimen as the answer for all forms of heart failure. The decision depends on the person’s diagnoses, treatment goals, existing medicines, and clinical circumstances.

There is also an important evidence gap. The facts available here do not establish definitive long-term primary cardiovascular outcome results for semaglutide plus an SGLT2 inhibitor in non-diabetic HFpEF populations. We should not turn subgroup or post-hoc observations into a firm claim about mortality or hospitalization benefits in a population that has not been settled by prospective outcome evidence.

For patients, the useful conversation is usually specific rather than abstract: Which problem is most pressing right now? Repeated congestion and admissions? Limited walking from breathlessness and excess weight? Diabetes and kidney risk alongside heart failure? Naming the priority helps explain why a clinician might choose one class first, add another, or focus on other aspects of care.

What the evidence can and cannot settle

The SGLT2 inhibitor trials give clinicians a strong basis for discussing heart-failure event reduction across HFrEF and HFpEF, with benefits reported regardless of diabetes status. Semaglutide’s STEP-HFpEF findings add a different kind of evidence: improvement in symptoms, physical limitations, exercise capacity, and weight over 52 weeks in people with obesity and HFpEF.

The unanswered questions matter too. The evidence summarized here does not supply a direct, long-term head-to-head trial comparing GLP-1 receptor agonists with SGLT2 inhibitors as primary therapies for hard mortality outcomes in HFrEF without diabetes. It also does not settle long-term primary cardiovascular outcomes for combination semaglutide and SGLT2 inhibitor therapy in non-diabetic HFpEF. Those gaps are reasons to be precise, not reasons to dismiss what the trials have already shown.

In my clinic, I encourage patients to bring the treatment goal into the discussion. Ask whether a medicine is being considered to reduce heart-failure events, to improve weight and functional capacity, to manage diabetes, or to address several of these at once. The answer may include more than one therapy, but each should have a clear role.

The practical next steps are modest and useful: keep a current list of heart-failure and diabetes medicines for appointments; describe what activity brings on symptoms and how that has changed; and ask which outcome the proposed treatment is expected to improve. Those details help turn broad trial results into a plan that fits a person’s daily baseline, while leaving room to adjust as the evidence and the patient’s needs evolve.